The NapaJen team is building a Pipeline of therapeutics addressing significant market needs through augmentation of immuno-oncology treatments as well as organ and stem cell transplantation opportunities. By loading different oligo drugs onto its cell-specific drug delivery platform, NapaJen has made both “precision-targeted immunosuppressive” treatment as well as “controlled immuno-stimulation” possible in preclinical models.
NJA-730 for Acute Graft versus Host Disease (aGvHD)
NJA-730, NapaJen’s lead therapeutic compound is an anti-CD40 oligo complexed with SPG for the treatment of acute Graft versus Host Disease (aGvHD) in Hematological Cancer Patients undergoing Stem Cell Transplantations. Clinical trials are expected in 2018. NapaJen‘s oligonucleotide-SPG complex uses the Dectin-1 receptor to specifically target immature dendritic cells (not antigen exposed) to inhibit the CD40 protein production which is critical in dendritic cell semi-maturation, hence allowing for tolerance. NapaJen‘s approach is distinct from other anti-CD40 drugs since it does not disrupt CD40 expression in B-cells and spares overall immune homeostasis. Results of nonclinical pharmacology studies of NJA-730 collectively indicate that the in vivo efficacious dose of a mouse- orthologous anti-CD40 oligonucleotide is 100- to 1000-fold lower than that reported from other oligonucleotide drugs targeting similar cell types; making it likely that NapaJen’s approach will preserve patient quality of life by reducing side effects.